{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:52:57Z","timestamp":1790139177947,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.005","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:34:07Z","timestamp":1760222047000},"page":"e241-e247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma\u2013Experience from Asian Countries"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-8872","authenticated-orcid":false,"given":"Cinnie","family":"Soekojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5174-7361","authenticated-orcid":false,"given":"Shimin Jasmine","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Tao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8436","authenticated-orcid":false,"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9515-0017","authenticated-orcid":false,"given":"Hiroyuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-6585","authenticated-orcid":false,"given":"Uday","family":"Yanamandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-2226","authenticated-orcid":false,"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.005_bib0001","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00277-012-1506-2","article-title":"Low incidence of thromboembolism in relapsed\/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan","volume":"91","author":"Wu","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.10.005_bib0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00277-009-0807-6","article-title":"Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide","volume":"89","author":"Koh","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.10.005_bib0003","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","article-title":"Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma","volume":"107","author":"Miyakoshi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.005_bib0004","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cas.12335","article-title":"Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization","volume":"105","author":"Yoshizawa","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2025.10.005_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.005_bib0006","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1016\/j.clml.2025.10.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35665","article-title":"Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1","volume":"131","author":"Cai","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.10.005_bib0008","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/jjco\/hyae068","article-title":"Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3","volume":"54","author":"Iida","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.005_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7536","article-title":"Real-world schedule de-escalation of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Tan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.005_bib0010","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1007\/s00277-025-06529-1","article-title":"De-escalated Teclistamab dosing in relapsed\/refractory multiple myeloma: Czech myeloma group real-world evidence analysis","volume":"104","author":"Stork","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.10.005_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2025.10.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35665","article-title":"Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed\/refractory multiple myeloma from the China cohort of MajesTEC-1","volume":"131","author":"Cai","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.10.005_bib0013","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.clml.2024.03.002","article-title":"BCMA directed bispecific antibody induced tumor flare in multiple myeloma","volume":"24","author":"Nagarajan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.10.005_bib0014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2025.10.005_bib0015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clml.2025.10.005_bib0016","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.10.005_bib0017","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2025.10.005_bib0018","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.10.005_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.005_bib0021","unstructured":"World Health Organization. Global Tuberculosis Report 2024. 2024. Geneva: WHO; 2024. Available from: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024who.int+1. Accessed 20 March, 2025."},{"key":"10.1016\/j.clml.2025.10.005_bib0022","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2021022","article-title":"Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications","volume":"43","author":"Husain","year":"2021","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.clml.2025.10.005_bib0023","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41598-020-58459-9","article-title":"Factors associated with false negative interferon-\u03b3 release assay results in patients with tuberculosis: a systematic review with meta-analysis","volume":"10","author":"Yamasue","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.clml.2025.10.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211028437","article-title":"Features of indeterminate results of QuantiFERON-TB gold in-tube test in patients with haematological malignancies","volume":"12","author":"Huang","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2025.10.005_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.clml.2025.10.005_bib0026","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2025.10.005_bib0027","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.005_bib0028","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3324\/haematol.2023.283003","article-title":"Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen","volume":"108","author":"Palmen","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.005_bib0029","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.005_bib0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.clml.2025.10.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100097","article-title":"Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab","volume":"2","author":"Pei","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2025.10.005_bib0032","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1080\/1744666X.2024.2384060","article-title":"Pathogen-specific cell-mediated immunity to guide the management of cytomegalovirus in solid organ transplantation: state of the art clinical review","volume":"20","author":"Razonable","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clml.2025.10.005_bib0033","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.10.005_bib0034","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.10.005_bib0035","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood.2021014989","article-title":"Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy","volume":"139","author":"Terpos","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.005_bib0036","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:17:51Z","timestamp":1770650271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042454"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma\u2013Experience from Asian Countries","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}